Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Update

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 184,300 shares, an increase of 1,136.9% from the March 31st total of 14,900 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily volume of 254,300 shares, the days-to-cover ratio is presently 0.7 days.

Shionogi & Co., Ltd. Stock Down 0.5 %

SGIOY stock traded down $0.04 during midday trading on Friday, reaching $8.37. 32,435 shares of the company were exchanged, compared to its average volume of 125,886. The company has a market cap of $14.24 billion, a price-to-earnings ratio of 14.52, a price-to-earnings-growth ratio of 2.37 and a beta of 0.21. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.01 and a current ratio of 7.64. Shionogi & Co., Ltd. has a 1-year low of $6.22 and a 1-year high of $8.72. The stock's 50-day simple moving average is $7.73 and its 200 day simple moving average is $7.26.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $0.16 earnings per share (EPS) for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. On average, equities analysts forecast that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.